Heparanase procoagulant activity is elevated in women using oral contraceptives

Human Reproduction

Volumn 28, Issue 9, 2013, Pages 2372-2380

  Matan, Moshe ^a   Axelman, Elena ^b   Brenner, Benjamin ^b   Nadir, Yona ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

coagulation; estrogen; heparanase; oral contraceptives; tamoxifen

Indexed keywords

CHROMOGENIC SUBSTRATE; HEPARANASE; ORAL CONTRACEPTIVE AGENT; TAMOXIFEN;

ADULT; ARTICLE; BLOOD CLOTTING; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL CULTURE; IN VITRO STUDY;

COAGULATION; ESTROGEN; HEPARANASE; ORAL CONTRACEPTIVES; TAMOXIFEN;

ADULT; BLOOD COAGULATION; CASE-CONTROL STUDIES; CELL LINE; CONTRACEPTIVES, ORAL; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; GLUCURONIDASE; HUMANS; ISRAEL; MAMMARY GLANDS, HUMAN; RECEPTORS, ESTROGEN; RISK; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION; TAMOXIFEN; THROMBOPHILIA; THROMBOPLASTIN; YOUNG ADULT;

EID: 84883169320     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/det257     Document Type: Article

References (23)

1. Calabrese EJ. Estrogen and related compounds: biphasic dose responses. Crit Rev Toxicol 2001;31:503-515. (Pubitemid 32706314)
2. Cohen I, Maly B, Simon I, Meirovitz A, Pikarsky E, Zcharia E, Peretz T, Vlodavsky I, Elkin M. Tamoxifen induces heparanase expression in estrogen receptor-positive breast cancer. Clin Cancer Res 2007; 13:4069-4077. (Pubitemid 47105967)
3. Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer 2004;101:439-449. (Pubitemid 38970595)
4. Dempsey LA, Brunn GJ, Platt JL. Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci 2000;25:349-351. (Pubitemid 30497237)
5. Elkin M, Cohen I, Zcharia E, Orgel A, Guatta-Rangini Z, Peretz T, Vlodavsky I, Kleinman HK. Regulation of heparanase gene expression by estrogen in breast cancer. Cancer Res 2003;63:8821-8826. (Pubitemid 38064061)
6. Freeman C, Parish CR. Human platelet heparanase: purification, characterization and catalytic activity. Biochem J 1998; 330: 1341-1350. (Pubitemid 28162014)
7. Gingis-Velitski S, Zetser A, Flugelman MY, Vlodavsky I, Ilan N. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 2004;279:23536-23541. (Pubitemid 38685666)
8. Goldshmidt O, Zcharia E, Cohen M, Aingorn H, Cohen I, Nadav L, Katz BZ, Geiger B, Vlodavsky I. Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J 2003;17:1015-1025. (Pubitemid 36676388)
9. Hernandez RK, Sorensen HT, Pedersen L, Jacobsen J, Lash TL. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer 2009; 115:4442-4449.
10. Nadir Y, Brenner B, Zetser A, Ilan N, Shafat I, Zcharia E, Goldshmidt O, Vlodavsky I. Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost 2006;4:2443-2451. (Pubitemid 44575440)
11. Nadir Y, Brenner B, Fux L, Shafat I, Attias J, Vlodavsky I. Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII. Haematologica 2011a;95:1927-1934.
12. Nadir Y, Kenig Y, Drugan A, Shafat I, Brenner B. An assay to evaluate heparanase procoagulant activity. Thromb Res 2011b;128:e3-8.
13. Parish CR, Freeman C, Hulett MD. Heparanase:akey enzyme involvedincell invasion. Biochim Biophys Acta 2001;1471:M99-M108.
14. Peled E, Rovitsky A, Axelman E, Norman D, Brenner B, Nadir Y. Increased heparanase level and procoagulant activity in orthopedic surgery patients receiving prophylactic dose of enoxaparin. Thromb Res 2012; 130:129-134.
15. Pikas DS, Li JP, Vlodavsky I, Lindahl U. Substrate specificity of heparanases from human hepatoma and platelets.JBiol Chem 1998;273:18770-18777. (Pubitemid 28366261)
16. Pinto S, Bruni V, Rosati D, Prisco D, Costanzo M, Giusti B, Abbate R. Effects of estrogen replacement therapy on thrombin generation. Thromb Res 1997; 85:185-193. (Pubitemid 27145455)
17. Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, Nicolaes GA, Meijers JC, Bouma BN, Buller HR, Prins MH, Tans G. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised crossover study. Lancet 1999;354:2036-2040.
18. Shafat I, Zcharia E, Nisman B, Nadir Y, Nakhoul F, Vlodavsky I, Ilan N. An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun 2006;341:958-963. (Pubitemid 43221759)
19. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001; 108:341-347. (Pubitemid 32730777)
20. Wakeling AE. The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res Treat 1993;25:1-9.
21. Wiegratz I, Stahlberg S, Manthey T, Sanger N, Mittmann K, Lange E, Mellinger U, Kuhl H. Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters. Contraception 2008;78:384-391.
22. Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schubert S, Flugelman MY, Vlodavsky I, Ilan N. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 2004;117:2249-2258. (Pubitemid 38807493)
23. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 2006;66:1455-1463. (Pubitemid 43259926)